{"entity":{"id":"philippe-armand","kind":"person","name":"Philippe Armand","aka":[],"tldr":"Boston lymphoma doctor who led KEYNOTE-170, the trial that showed pembrolizumab can control relapsed primary mediastinal B-cell lymphoma, and who helped bring PD-1 blockade to Hodgkin lymphoma.","summary":"Philippe Armand is a lymphoma specialist at Dana-Farber Cancer Institute. He was first author of the 2019 Journal of Clinical Oncology report of KEYNOTE-170, in which pembrolizumab produced durable responses in relapsed or refractory primary mediastinal large B-cell lymphoma, supporting its approval in that setting, and was a lead investigator of the trials of nivolumab and pembrolizumab in relapsed classical Hodgkin lymphoma.","asOf":"2026-09-18","links":[],"tags":["lymphoma","immunotherapy","trialist"],"related":[],"cancers":["primary-mediastinal-b-cell-lymphoma","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-keynote-170-pembrolizumab-pmbcl-armand-jco-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Lymphoma specialist, Dana-Farber Cancer Institute","institutionId":"dana-farber","specialisms":["Hodgkin lymphoma","Primary mediastinal B-cell lymphoma","Checkpoint inhibitors in lymphoma"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Armand%5BAuthor%5D"}],"papers":[]},"route":"/people/philippe-armand/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"primary-mediastinal-b-cell-lymphoma","kind":"cancer","name":"Primary mediastinal (thymic) large B-cell lymphoma","route":"/cancers/primary-mediastinal-b-cell-lymphoma/"}],"institution":[{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/"}],"paper":[{"id":"paper-keynote-170-pembrolizumab-pmbcl-armand-jco-2019","kind":"paper","name":"KEYNOTE-170: pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma","route":"/key-papers/paper-keynote-170-pembrolizumab-pmbcl-armand-jco-2019/"}]}}